In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.
Identifieur interne : 002F14 ( PubMed/Corpus ); précédent : 002F13; suivant : 002F15In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.
Auteurs : Alexander Gerhard ; Iris Trender-Gerhard ; Federico Turkheimer ; Niall P. Quinn ; Kailash P. Bhatia ; David J. BrooksSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Basal Ganglia (physiopathology), Basal Ganglia (radionuclide imaging), Brain Stem (physiopathology), Brain Stem (radionuclide imaging), Carbon Radioisotopes (diagnostic use), Cell Death (physiology), Female, Frontal Lobe (physiopathology), Frontal Lobe (radionuclide imaging), Humans, Image Processing, Computer-Assisted, Isoquinolines (diagnostic use), Magnetic Resonance Imaging, Male, Microglia (physiology), Microglia (radionuclide imaging), Middle Aged, Neurodegenerative Diseases (physiopathology), Neurodegenerative Diseases (radionuclide imaging), Neurons (physiology), Receptors, GABA-A (physiology), Reference Values, Stereoisomerism, Supranuclear Palsy, Progressive (physiopathology), Supranuclear Palsy, Progressive (radionuclide imaging).
- MESH :
- chemical , diagnostic use : Carbon Radioisotopes, Isoquinolines.
- physiology : Cell Death, Microglia, Neurons, Receptors, GABA-A.
- physiopathology : Basal Ganglia, Brain Stem, Frontal Lobe, Neurodegenerative Diseases, Supranuclear Palsy, Progressive.
- radionuclide imaging : Basal Ganglia, Brain Stem, Frontal Lobe, Microglia, Neurodegenerative Diseases, Supranuclear Palsy, Progressive.
- Aged, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Reference Values, Stereoisomerism.
Abstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem nuclei, and frontal cortex. [11C](R)-PK11195 PET is a marker of peripheral benzodiazepine binding sites (PBBS) expressed by activated microglia. We have used [11C](R)-PK11195 PET to demonstrate in vivo the degree and distribution of the glial response to the degenerative process in four patients with PSP. Compared to normal age-matched controls, the PSP patient group showed significantly increased mean [11C](R)-PK11195 binding in the basal ganglia, midbrain, the frontal lobe, and the cerebellum. Two of the patients were rescanned after 6 to 10 months and during that time the level of microglial activation remained stable. [11C](R)-PK11195 PET reveals a pattern of increased microglial activation in PSP patients involving cortical and subcortical regions that corresponds well with the known distribution of neuropathological changes. [11C](R)-PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP.
DOI: 10.1002/mds.20668
PubMed: 16108021
Links to Exploration step
pubmed:16108021Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.</title><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation><nlm:affiliation>MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, and National Hospital for Neurology and Neurosurgery, London, United Kingdom. alexander.gerhard@csc.mrc.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Trender Gerhard, Iris" sort="Trender Gerhard, Iris" uniqKey="Trender Gerhard I" first="Iris" last="Trender-Gerhard">Iris Trender-Gerhard</name></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P" last="Bhatia">Kailash P. Bhatia</name></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J" last="Brooks">David J. Brooks</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20668</idno><idno type="RBID">pubmed:16108021</idno><idno type="pmid">16108021</idno><idno type="wicri:Area/PubMed/Corpus">002F14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.</title><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation><nlm:affiliation>MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, and National Hospital for Neurology and Neurosurgery, London, United Kingdom. alexander.gerhard@csc.mrc.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Trender Gerhard, Iris" sort="Trender Gerhard, Iris" uniqKey="Trender Gerhard I" first="Iris" last="Trender-Gerhard">Iris Trender-Gerhard</name></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P" last="Bhatia">Kailash P. Bhatia</name></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J" last="Brooks">David J. Brooks</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Basal Ganglia (physiopathology)</term><term>Basal Ganglia (radionuclide imaging)</term><term>Brain Stem (physiopathology)</term><term>Brain Stem (radionuclide imaging)</term><term>Carbon Radioisotopes (diagnostic use)</term><term>Cell Death (physiology)</term><term>Female</term><term>Frontal Lobe (physiopathology)</term><term>Frontal Lobe (radionuclide imaging)</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Isoquinolines (diagnostic use)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Microglia (physiology)</term><term>Microglia (radionuclide imaging)</term><term>Middle Aged</term><term>Neurodegenerative Diseases (physiopathology)</term><term>Neurodegenerative Diseases (radionuclide imaging)</term><term>Neurons (physiology)</term><term>Receptors, GABA-A (physiology)</term><term>Reference Values</term><term>Stereoisomerism</term><term>Supranuclear Palsy, Progressive (physiopathology)</term><term>Supranuclear Palsy, Progressive (radionuclide imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Carbon Radioisotopes</term><term>Isoquinolines</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cell Death</term><term>Microglia</term><term>Neurons</term><term>Receptors, GABA-A</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term><term>Brain Stem</term><term>Frontal Lobe</term><term>Neurodegenerative Diseases</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Basal Ganglia</term><term>Brain Stem</term><term>Frontal Lobe</term><term>Microglia</term><term>Neurodegenerative Diseases</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Reference Values</term><term>Stereoisomerism</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem nuclei, and frontal cortex. [11C](R)-PK11195 PET is a marker of peripheral benzodiazepine binding sites (PBBS) expressed by activated microglia. We have used [11C](R)-PK11195 PET to demonstrate in vivo the degree and distribution of the glial response to the degenerative process in four patients with PSP. Compared to normal age-matched controls, the PSP patient group showed significantly increased mean [11C](R)-PK11195 binding in the basal ganglia, midbrain, the frontal lobe, and the cerebellum. Two of the patients were rescanned after 6 to 10 months and during that time the level of microglial activation remained stable. [11C](R)-PK11195 PET reveals a pattern of increased microglial activation in PSP patients involving cortical and subcortical regions that corresponds well with the known distribution of neuropathological changes. [11C](R)-PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16108021</PMID><DateCreated><Year>2006</Year><Month>01</Month><Day>19</Day></DateCreated><DateCompleted><Year>2006</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2014</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.</ArticleTitle><Pagination><MedlinePgn>89-93</MedlinePgn></Pagination><Abstract><AbstractText>Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem nuclei, and frontal cortex. [11C](R)-PK11195 PET is a marker of peripheral benzodiazepine binding sites (PBBS) expressed by activated microglia. We have used [11C](R)-PK11195 PET to demonstrate in vivo the degree and distribution of the glial response to the degenerative process in four patients with PSP. Compared to normal age-matched controls, the PSP patient group showed significantly increased mean [11C](R)-PK11195 binding in the basal ganglia, midbrain, the frontal lobe, and the cerebellum. Two of the patients were rescanned after 6 to 10 months and during that time the level of microglial activation remained stable. [11C](R)-PK11195 PET reveals a pattern of increased microglial activation in PSP patients involving cortical and subcortical regions that corresponds well with the known distribution of neuropathological changes. [11C](R)-PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP.</AbstractText><CopyrightInformation>Copyright (c) 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, and National Hospital for Neurology and Neurosurgery, London, United Kingdom. alexander.gerhard@csc.mrc.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trender-Gerhard</LastName><ForeName>Iris</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Turkheimer</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Niall P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U120036861</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120085814</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>85340-56-3</RegistryNumber><NameOfSubstance UI="C037850">PK 11195</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001933">Brain Stem</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002250">Carbon Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005625">Frontal Lobe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007091">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007546">Isoquinolines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019636">Neurodegenerative Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011963">Receptors, GABA-A</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013237">Stereoisomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20668</ArticleId><ArticleId IdType="pubmed">16108021</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002F14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16108021
|texte= In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16108021" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |